Indiana Funds Psilocybin Research for Veterans, First Responders and Treatment-Resistant Depression

Indiana is not known for leading the country on drug-policy reform. Recreational cannabis remains illegal in the state, and psilocybin is still classified as a Schedule I controlled substance under federal and Indiana law.

Yet Indiana is quietly becoming an important participant in psychedelic medical research.

A state-supported clinical trial at the Indiana University School of Medicine will examine whether psilocybin-assisted psychotherapy can safely reduce depression symptoms and substance-use severity among veterans and first responders. The participants will have both treatment-resistant depression and a co-occurring substance-use disorder.

The study is supported in part by Indiana’s Therapeutic Psilocybin Research Fund, which lawmakers created in 2024. Indiana’s latest budget allocated $300,000 to the fund across the current two-year budget period.

It is a relatively modest investment by government standards. However, it represents something much more significant: a traditionally conservative state is using public money to investigate whether the active psychedelic compound in “magic mushrooms” could become a legitimate mental-health treatment.

What Is Indiana’s Therapeutic Psilocybin Research Fund?

Indiana lawmakers established the Therapeutic Psilocybin Research Fund through House Bill 1259 in 2024.

The fund is administered by the state’s Division of Mental Health and Addiction and was created to provide financial assistance to Indiana research institutions conducting clinical studies involving psilocybin.

Importantly, the legislation did not legalize psilocybin for personal, recreational or general therapeutic use. Instead, it created a regulated pathway through which qualified institutions can study the compound as a potential treatment for mental-health and medical conditions.

That distinction matters.

Indiana is not opening psychedelic dispensaries or authorizing unregulated psilocybin retreats. It is investing in controlled clinical research designed to determine who might benefit, what dose may be effective, what risks may be involved and how psychedelic treatments should be delivered.

The Indiana General Assembly’s official summary of House Bill 1259 describes the fund as a source of financial assistance for Indiana institutions researching the therapeutic use of psilocybin.

According to Axios Indianapolis, state Senator Scott Baldwin plans to advocate for continued funding during Indiana’s next budget-writing session. The Indiana Department of Veterans Affairs and Mental Health America of Indiana have reportedly already requested continued support.

Inside Indiana University’s New Psilocybin Clinical Trial

The Indiana University study is more specific than simply asking whether psilocybin “works.”

Researchers are attempting to determine which of three doses—5 milligrams, 10 milligrams or 25 milligrams—can be safely and effectively combined with psychotherapy for veterans and first responders experiencing treatment-resistant depression and a co-occurring substance-use disorder.

The randomized, double-blind study expects to enroll approximately 50 participants. Each participant will receive one oral dose of psilocybin in a professionally supervised clinical environment.

The approximately 14-week research protocol includes:

• Two clinical intake sessions
• Three psychotherapy sessions before psilocybin administration
• One supervised dosing session lasting approximately eight to 10 hours
• Three psychotherapy sessions following the dosing experience
• Repeated assessments of depression symptoms and substance use
• Brain imaging before and after treatment
• Continued safety monitoring and follow-up

The trial is not studying casual or unsupervised mushroom use. It is studying a structured treatment model in which screening, preparation, supervision, psychotherapy and follow-up are all considered part of the intervention.

That is an essential difference frequently lost in headlines about psychedelic medicine.

Why Compare 5, 10 and 25 Milligrams of Psilocybin?

One of the most important unanswered questions in psychedelic medicine is how much of the substance is actually necessary to produce a therapeutic benefit.

A larger dose may create a more intense psychedelic experience, but greater intensity does not automatically mean a better clinical outcome. Higher doses may also increase acute anxiety, confusion, elevated blood pressure or other adverse reactions.

Lower doses may be easier for patients to tolerate but might not produce the same therapeutic effects.

By comparing 5-, 10- and 25-milligram doses, the IU research team can examine whether benefits and risks change with dose. Researchers will also use brain imaging and repeated behavioral assessments to investigate the neurobiological processes that may accompany any improvement.

A prominent 2022 Phase 2 study found that a single 25-milligram dose reduced depression scores more than a 1-milligram comparison dose after three weeks. The 10-milligram dose did not produce the same statistically significant result, and adverse effects were reported. The researchers concluded that larger and longer trials were still necessary. The findings were published in the New England Journal of Medicine.

More recent evidence has added nuance rather than delivering a simple victory.

A 2026 randomized trial involving 144 adults with treatment-resistant depression did not meet its primary endpoint. Secondary measures nevertheless suggested potentially meaningful reductions in depression symptoms among participants who received 25 milligrams of psilocybin. Researchers also reported important safety signals, including acute adverse reactions and two serious reactions in the 25-milligram group. Those results were published in JAMA Psychiatry.

That combination of encouraging signals and unresolved questions helps explain why Indiana’s dose-comparison study is valuable.

Why Focus on Veterans and First Responders?

Veterans and first responders can experience repeated exposure to trauma, death, injury, violence and extreme stress. Some develop depression, PTSD, alcohol or drug-use disorders, while others experience several of these conditions simultaneously.

These conditions can reinforce one another.

Someone may use alcohol or another substance to cope with depression, intrusive memories, sleeplessness or emotional distress. Substance use can then worsen mood, relationships, employment and physical health, creating a difficult cycle.

Treatment-resistant depression generally refers to depression that has not adequately improved after multiple conventional treatments. When it occurs alongside a substance-use disorder, treatment becomes even more complicated.

The IU trial is designed around that real-world complexity. Instead of excluding everyone with co-occurring substance-use problems, researchers are investigating whether psilocybin-assisted psychotherapy could address depression and substance-use severity together.

Although PTSD is part of the broader conversation about psychedelics and veteran mental health, the registered Indiana study is specifically focused on treatment-resistant depression with a co-occurring substance-use disorder. Psilocybin should not yet be described as a proven PTSD treatment.

Could Psilocybin Help With Substance-Use Disorders?

Early studies involving alcohol, tobacco, cocaine and other substance-use disorders have generated interest in psilocybin-assisted treatment.

Researchers do not generally describe psilocybin as a medication that simply blocks cravings. The theory is more complex. Under controlled conditions, psilocybin may temporarily alter rigid patterns of thought, emotional processing and self-perception. Psychotherapy may then help a person translate that experience into lasting behavioral change.

The drug is therefore being studied as a possible catalyst within treatment—not as a magic pill and certainly not as a substitute for therapy.

A 2025 systematic review found encouraging results across several small studies involving alcohol and tobacco use, while also emphasizing the limited size and quality of the existing evidence. More rigorous randomized trials remain necessary before researchers can determine which substance-use disorders, patient populations and treatment models are most likely to benefit.

Indiana’s study could be especially informative because it will measure depression and substance-use outcomes in the same participants.

Psilocybin Research Is Moving Into a More Rigorous Era

The psychedelic research conversation is changing.

For years, public discussion was often divided between exaggerated enthusiasm and reflexive prohibition. One side treated psychedelics as miracle cures, while the other treated them as substances with no possible medical value.

Clinical science requires something more disciplined.

Researchers must account for expectancy effects, functional unblinding, therapist influence, patient selection, psychiatric risks and the difficulty of creating a convincing placebo for a drug that produces obvious perceptual effects.

They must also determine which parts of treatment are essential. Is the therapeutic benefit primarily pharmacological? How much depends on preparation, therapeutic support, the subjective experience or post-session integration? Can effective protocols be delivered affordably and consistently outside specialized research centers?

In July 2026, the U.S. Food and Drug Administration finalized its guidance for clinical investigations involving psychedelic drugs. The guidance addresses trial design, safety monitoring, psychological support and other challenges unique to psychedelic research. It signals that federal regulators are taking the field seriously while demanding stronger evidence from developers and researchers. The full guidance is available through the FDA.

The National Institutes of Health has also identified psilocybin research as an area of scientific interest, including research into benefits, risks, drug interactions, biomarkers and the effects of factors such as genetics, age and medical conditions.

That does not guarantee approval. It means psychedelic research is increasingly being evaluated through the same demanding scientific and regulatory systems applied to other investigational medicines.

Research Funding Does Not Mean Psilocybin Has Been Legalized

Indiana’s investment does not make psilocybin legal for the public.

Psilocybin remains a Schedule I controlled substance under federal law, and the FDA has not approved it as a standard treatment for depression, PTSD, addiction or any other medical condition.

Clinical trials operate under regulatory approvals, controlled drug-handling requirements, participant screening and professional supervision. Their findings should not be interpreted as instructions for self-treatment.

People with personal or family histories of psychotic disorders, certain bipolar-spectrum conditions, cardiovascular risks or medication interactions may face particular concerns. Even screened participants can experience fear, confusion, nausea, increased blood pressure or difficult psychological reactions during a dosing session.

The controlled environment is not an incidental part of psilocybin research. It is part of the safety model.

Anyone experiencing depression, suicidal thoughts, PTSD or a substance-use disorder should seek help from a qualified medical or mental-health professional. Psychedelics should never be treated as a replacement for emergency care or professional support.

Why Indiana’s Decision Matters Nationally

Indiana’s approach may provide a model for states that are not ready to legalize psychedelics but do not want political caution to prevent scientific investigation.

State-funded research can help answer questions that commercial drug developers may not prioritize. Those questions include how psychedelic therapy affects veterans, first responders, people with multiple diagnoses and populations often underrepresented in clinical trials.

It can also build local expertise.

If a psilocybin treatment eventually receives FDA approval, states will need trained clinicians, treatment protocols, medical infrastructure and realistic information about costs and safety. Supporting research now gives Indiana an opportunity to participate in developing that knowledge instead of waiting for other states to produce it.

Senator Baldwin told Axios that legalization discussions are unlikely to advance until lawmakers can examine the study results. That may frustrate advocates seeking immediate reform, but it also reveals why continued funding is important: without research, lawmakers can continue claiming that the necessary evidence does not exist.

Indiana has started building that evidence.

The Bottom Line

Indiana has not legalized magic mushrooms. It has done something more limited but still meaningful: the state has acknowledged that psilocybin’s medical potential deserves rigorous investigation.

The Indiana University trial will compare three doses of psilocybin-assisted psychotherapy in veterans and first responders with treatment-resistant depression and substance-use disorders. Researchers will monitor safety, depression symptoms, substance-use severity and changes in brain activity.

The results may be positive, negative or mixed. That uncertainty is precisely why the research needs to happen.

Responsible psychedelic education is not about declaring psilocybin a miracle cure. It is about replacing decades of stigma and speculation with evidence. Indiana’s investment represents another step in that direction—and potentially an important one for veterans, first responders and other patients who have not found adequate relief through existing treatments.

This article is for educational purposes only and does not constitute medical or legal advice. Psilocybin remains federally illegal outside authorized research and limited jurisdiction-specific programs.